New Approach Methodologies (NAMs): A Complete Guide for Researchers
Key Takeaways
- NAMs is an umbrella term covering all non-animal methods for drug safety and efficacy testing
- Major categories: in vitro (cell-based), in chemico (chemical), in silico (computational), and integrated approaches
- The FDA, EPA, EMA, and OECD all have active NAMs acceptance programs
- NAMs can reduce drug development costs by 10-40% in preclinical phases
- Validation requires demonstrated relevance, reliability, and defined context of use
What Are New Approach Methodologies?
New approach methodologies (NAMs) is a term used by regulatory agencies to describe any technology, methodology, approach, or combination thereof that can provide information on drug hazard and risk assessment that avoids the use of intact animals. The term encompasses a broad spectrum of tools, from simple chemical reactivity assays to complex multi-organ microphysiological systems and computational models.
The term was originally coined by the U.S. Environmental Protection Agency (EPA) and has since been adopted by the FDA, European Medicines Agency (EMA), Organisation for Economic Co-operation and Development (OECD), and regulatory bodies worldwide. NAMs represents a shift from asking "what does this drug do to a rat?" to "what does this drug do to human biology?"
The Four Categories of NAMs
1. In Vitro Methods (Cell and Tissue-Based)
In vitro NAMs use living human cells and tissues outside the body to assess drug safety and efficacy. These range in complexity from simple 2D cell monolayers to complex 3D organ systems.
- Organ-on-chip (OoC): Microfluidic devices with living cells that replicate organ physiology including mechanical forces and fluid flow. Currently available for lung, liver, kidney, intestine, heart, brain, and skin.
- Organoids: Self-organizing 3D cellular structures derived from stem cells that recapitulate organ architecture. Patient-derived organoids enable personalized drug testing.
- 3D spheroids and microtissues: Aggregated cell clusters that better represent tissue-level responses than flat cell cultures. Used extensively for liver toxicity screening.
- Reconstructed human tissues: Commercially available tissue models (e.g., EpiDerm for skin, EpiAirway for respiratory) that are OECD-validated as animal test replacements.
- Bioprinted tissues: 3D-printed constructs using living cells and bioinks that replicate tissue architecture with high spatial control.
2. In Chemico Methods (Chemical Reactivity)
In chemico NAMs use cell-free chemical reactions to assess specific toxicological endpoints. These are the simplest and most standardized NAMs category.
- Direct Peptide Reactivity Assay (DPRA): Tests whether a chemical can bind to proteins, a key event in skin sensitization. OECD Test Guideline 442C.
- KeratinoSens assay: Tests activation of the Keap1-Nrf2 pathway, the molecular initiating event for skin sensitization. OECD Test Guideline 442D.
- Amino acid derivative reactivity assay (ADRA): Alternative to DPRA that measures chemical reactivity with nucleophilic amino acid derivatives.
3. In Silico Methods (Computational)
In silico NAMs use computational models and algorithms to predict drug behavior based on chemical structure, biological data, and mathematical modeling.
- QSAR (Quantitative Structure-Activity Relationship): Mathematical models that predict biological activity based on chemical structure. Used for toxicity screening of large compound libraries.
- Read-across: Uses data from tested chemicals to predict the hazard of structurally similar untested chemicals. Accepted by ECHA for REACH registration.
- PBPK modeling (Physiologically-Based Pharmacokinetic): Mathematical models that simulate drug absorption, distribution, metabolism, and excretion using physiological parameters.
- Digital twins: Patient-specific computational models that integrate multi-omic data to predict individual drug responses. Emerging technology with applications in precision medicine.
- Molecular docking and dynamics: Computational simulation of drug-target interactions at the atomic level. Used for virtual screening and lead optimization.
4. Integrated Approaches (IATA)
Integrated Approaches to Testing and Assessment (IATA) combine multiple NAMs into structured decision frameworks that collectively provide enough evidence to replace an animal test.
- Defined approaches (DA): Standardized combinations of information sources (e.g., in silico + in chemico + in vitro) with fixed data interpretation procedures. Several DAs for skin sensitization are now OECD-validated.
- Weight-of-evidence approaches: Expert-driven integration of multiple NAMs results, existing data, and physicochemical properties to make hazard decisions.
- Adverse Outcome Pathways (AOPs): Frameworks that map the biological mechanisms from a molecular initiating event to an adverse health outcome. AOPs guide selection of NAMs that address key events in the pathway.
Regulatory Acceptance Status
| Agency | NAMs Program | Key Actions |
|---|---|---|
| FDA (US) | ISTAND, Alternative Methods Program | Modernization Act permits NAMs as alternatives; qualified organ-on-chip platforms through ISTAND; publishes annual NAMs acceptance data |
| EPA (US) | NAMs Work Plan | Committed to eliminating mammalian study requirements by 2035; adopted NAMs for endocrine disruptor screening; published NAMs guidance for TSCA |
| EMA (EU) | 3Rs Strategy, SAWP | Scientific Advice Working Party (SAWP) provides NAMs-specific advice; published guidance on qualification of novel methodologies |
| OECD | Test Guidelines Programme | Published 30+ validated test guidelines for in vitro methods; developing guidelines for organ-on-chip and organoid systems |
| Health Canada | NAMs Science Hub | Established in 2023 to coordinate NAMs integration across food, drug, and device regulation |
Validation: The Path from Lab to Regulation
For a NAM to be accepted by regulators, it must demonstrate three core attributes:
- Relevance: The NAM measures or predicts a biologically meaningful endpoint that is related to the regulatory question (e.g., does this drug cause liver toxicity in humans?)
- Reliability: The NAM produces consistent, reproducible results within and between laboratories (intra- and inter-laboratory reproducibility)
- Defined context of use: The specific regulatory application for which the NAM is intended is clearly described, including the decision it informs and the limits of its applicability
The validation process typically involves:
- Intralaboratory development and optimization
- Transferability assessment (can other labs reproduce results?)
- Interlaboratory validation study (ring trial across 3+ labs)
- Retrospective or prospective analysis against reference data (typically animal study or clinical outcomes)
- Peer review and regulatory submission
- Formal acceptance (OECD test guideline, FDA qualification, etc.)
Cost and Time Advantages
NAMs offer measurable advantages in preclinical drug development economics:
- In silico screening can evaluate thousands of compounds in hours, compared to weeks for cell-based assays or months for animal studies
- Organ-on-chip studies typically cost $10,000-50,000 per study, compared to $100,000-500,000 for equivalent animal toxicology studies
- Organoid drug screening can test hundreds of patient-derived models in parallel, enabling population-level predictions from a single experiment
- Integrated NAMs approaches can reduce the preclinical phase from 3-6 years to 1-3 years for certain regulatory endpoints
The economic case for NAMs is becoming as compelling as the scientific case. Reducing preclinical costs and timelines while improving human predictiveness addresses the fundamental inefficiency of the current drug development model.
Challenges and Limitations
NAMs face several barriers to widespread adoption:
- Standardization gaps: Many advanced NAMs (organ-on-chip, organoids) lack standardized protocols, reference chemicals, and acceptance criteria
- Training and expertise: Transitioning from animal testing to NAMs requires new skills in microfluidics, stem cell biology, and computational modeling
- Regulatory inertia: Despite new frameworks, many regulatory reviewers are more familiar with animal data and may request additional justification for NAMs-based submissions
- Systemic endpoints: Reproductive toxicity, developmental neurotoxicity, and long-term carcinogenicity remain difficult to assess without whole-organism models
- Data infrastructure: No universal database exists for sharing NAMs validation data across institutions and regulatory jurisdictions
Explore NAMs Technologies
Patient Analog offers interactive simulations and in-depth guides for every major NAMs category.
NAMs Technology Hub Interactive Simulations